{"drugs":["Nilandron","Nilutamide"],"mono":[{"id":"923921-s-0","title":"Generic Names","mono":"Nilutamide"},{"id":"923921-s-1","title":"Dosing and Indications","sub":{"0":{"id":"923921-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Metastatic prostate cancer, In combination with an LHRH analog:<\/b> 300 mg ORALLY once daily for 30 days followed by 150 mg ORALLY once daily<\/li><li><b>Metastatic prostate cancer, In combination with surgical castration:<\/b> 300 mg ORALLY once daily for 30 days followed by 150 mg ORALLY once daily<\/li><\/ul>"},"1":{"id":"923921-s-1-5","title":"Pediatric Dosing","mono":"Safety and effectiveness in children not established"},"3":{"id":"923921-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Metastatic prostate cancer, In combination with surgical castration<br\/><b>Non-FDA Labeled Indications<\/b><br\/>Metastatic prostate cancer, In combination with an LHRH analog<br\/>"}}},{"id":"923921-s-2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/>Interstitial pneumonitis has been reported in 2% of patients in controlled clinical trials exposed to nilutamide. Reports of interstitial changes including pulmonary fibrosis that led to hospitalization and death have been reported rarely post-marketing. Symptoms included exertional dyspnea, cough, chest pain, and fever. A routine chest X-ray should be performed prior to initiating treatment and baseline pulmonary function tests may be considered. Patients should be instructed to report any new or worsening shortness of breath, and if symptoms occur, nilutamide should be discontinued until it can be determined if the symptoms are drug-related.<br\/>"},{"id":"923921-s-3","title":"Contraindications\/Warnings","sub":[{"id":"923921-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to nilutamide or any component of the preparation<\/li><li>severe hepatic impairment<\/li><li>severe respiratory insufficiency<\/li><\/ul>"},{"id":"923921-s-3-10","title":"Precautions","mono":"<ul><li>avoid intake of alcoholic beverages<\/li><li>immediately discontinue treatment if patient reports any new or worsening shortness of breath<\/li><li>immediately discontinue treatment if patient develops jaundice or their ALT rises above 2 times the upper limit of normal<\/li><\/ul>"},{"id":"923921-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"923921-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"923921-s-4","title":"Drug Interactions","sub":{"2":{"id":"923921-s-4-15","title":"Moderate","mono":"<ul><li>Fosphenytoin (probable)<\/li><li>Phenytoin (probable)<\/li><li>Theophylline (probable)<\/li><li>Warfarin (probable)<\/li><\/ul>"}}},{"id":"923921-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension<\/li><li><b>Endocrine metabolic:<\/b>Hot sweats<\/li><li><b>Gastrointestinal:<\/b>Constipation, Nausea<\/li><li><b>Neurologic:<\/b>Dizziness<\/li><li><b>Ophthalmic:<\/b>Abnormal vision<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Heart failure (3%)<\/li><li><b>Hematologic:<\/b>Aplastic anemia<\/li><li><b>Hepatic:<\/b>Hepatitis (1%), Increased liver enzymes, Marked (1%)<\/li><li><b>Respiratory:<\/b>Interstitial pneumonia (2%)<\/li><\/ul>"},{"id":"923921-s-6","title":"Drug Name Info","sub":{"0":{"id":"923921-s-6-17","title":"US Trade Names","mono":"Nilandron<br\/>"},"2":{"id":"923921-s-6-19","title":"Class","mono":"Antiandrogen<br\/>"},"3":{"id":"923921-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"923921-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},{"id":"923921-s-7","title":"Mechanism Of Action","mono":"Nilutamide is a nonsteroidal antiandrogen that inhibits testosterone's effects on androgen receptors. It interacts with these receptors to block the normal androgenic response.<br\/>"},{"id":"923921-s-8","title":"Pharmacokinetics","sub":[{"id":"923921-s-8-23","title":"Absorption","mono":"Oral: rapid and complete <br\/>"},{"id":"923921-s-8-24","title":"Distribution","mono":"Protein binding: moderate <br\/>"},{"id":"923921-s-8-25","title":"Metabolism","mono":"<ul><li>Hepatic; oxidation, extensive<\/li><li>Metabolites: metabolites with L- and D-isomer<\/li><\/ul>"},{"id":"923921-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 1.4% to 7%<\/li><li>Renal: 62%, less than 2% unchanged<\/li><\/ul>"},{"id":"923921-s-8-27","title":"Elimination Half Life","mono":"Nilutamide: 38 h to 59.1 h <br\/>"}]},{"id":"923921-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>take with or without food<\/li><li>initiate therapy on the day of or the day after surgical castration<\/li><\/ul>"},{"id":"923921-s-10","title":"Monitoring","mono":"<ul><li>serum prostate specific antigen and serum alkaline phosphatase<\/li><li>improvement in bone pain<\/li><li>routine chest X-ray and pulmonary function tests; prior to initiating treatment<\/li><li>serum transaminases; baseline and at regular intervals for the first 4 months of therapy, and periodically thereafter<\/li><li>liver function tests; at first sign of symptoms suggestive of liver-dysfunction (nausea\/vomiting, abdominal pain, and dark urine)<\/li><\/ul>"},{"id":"923921-s-11","title":"How Supplied","mono":"<b>Nilandron<\/b><br\/>Oral Tablet: 150 MG<br\/>"},{"id":"923921-s-12","title":"Toxicology","sub":[{"id":"923921-s-12-31","title":"Clinical Effects","mono":"<b>NILUTAMIDE<\/b><br\/>OVERDOSE: little human data.  ADVERSE EFFECTS include: pneumonitis (1-17%), hepatitis, nausea, dizziness, delayed adaptation to darkness (most common effect - incidence 13-57%). <br\/>"},{"id":"923921-s-12-32","title":"Treatment","mono":"<b>NILUTAMIDE <\/b><br\/><ul><li>Support: Treatment is symptomatic and supportive.<\/li><li>Decontamination: Activated charcoal, gastric lavage.<\/li><li>Monitoring of patient: Monitor respiratory function in symptomatic individual. Elevated sed rate, neutrophilia, and lymphopenia frequently present with pneumonitis. Chest x-ray, ABGs and PFTs may be indicated to evaluate for pneumonitis.  Monitor hepatic enzymes as indicated.<\/li><\/ul>"},{"id":"923921-s-12-33","title":"Range of Toxicity","mono":"<b>NILUTAMIDE<\/b><br\/>Little human data.  A 79-year-old man survived after ingesting 13 g (43 times maximum recommended dose); followed by gastric lavage and activated charcoal. <br\/>"}]},{"id":"923921-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may decrease the ability for eyes to adjust from light to dark. This effect may last from seconds to minutes. Patients should use caution when driving at night or through tunnels. Inform patient the effect can be alleviated by wearing tinted glasses.<\/li><li>This drug may cause hot flashes, constipation, nausea, or aplastic anemia.<\/li><li>Instruct patient to report new or worsening shortness of breath, as drug may cause pulmonary fibrosis.<\/li><li>Patient should also report signs\/symptoms of hepatic dysfunction, including jaundice.<\/li><li>Advise patient against sudden discontinuation of drug.<\/li><li>Patient should avoid drinking alcohol while taking this drug, as this may cause dizziness, hypotension, and facial flushing.<\/li><li>Advise patient to call healthcare professional if a dose is missed, as drug should be given on a regular schedule.<\/li><\/ul>"}]}